CJC-1295 and sermorelin are both GHRH analogues — synthetic versions of the hormone that tells the pituitary to release growth hormone. The core difference is duration: sermorelin mirrors the natural hormone and is cleared within minutes, while CJC-1295 was engineered for a multi-day half-life. Sermorelin also has the unusual distinction of having once been an approved medicine (Geref, since discontinued), while CJC-1295 has only early-phase human data.
| Attribute | CJC-1295 | Sermorelin |
|---|---|---|
| Class | Long-acting GHRH analogue (GRF 1-29 with DAC modification) | GHRH analogue (GRF 1-29, matches the natural sequence) |
| Half-life | Days (albumin-binding DAC extends clearance) | Minutes — mimics the natural GHRH pulse |
| Human data | Early-phase studies: elevated GH/IGF-1 for days after single doses (JCEM 2006) | Clinical history as an approved product; diagnostic and paediatric GH-deficiency use |
| Regulatory status | Investigational — never approved | Formerly approved (Geref); withdrawn from market, no current authorisation |
| GH release pattern | Sustained elevation — flattens the natural pulse | Pulse-preserving — brief stimulation like the endogenous rhythm |
| WADA status | Prohibited | Prohibited |
| In the Body Pharm catalogue | Yes, combined with ipamorelin | No |
Sermorelin behaves like the hormone it copies: a brief signal that works with the body’s pulsatile GH rhythm and is gone in minutes. CJC-1295’s DAC modification binds albumin and stretches that signal across days, the property demonstrated in its 2006 human pharmacology studies. Whether a sustained elevation or a preserved pulse is preferable is an open question: the pulse is how GH physiology naturally operates, while sustained elevation produces larger cumulative IGF-1 exposure.
Sermorelin was an approved medicine, marketed as Geref for growth-hormone deficiency, before being discontinued for commercial reasons, so its human safety record comes from real clinical use. CJC-1295 never progressed past early-phase studies. Neither is an authorised medicine today, and both sit on the WADA prohibited list.
GHRH analogues amplify the GH pulse; secretagogues such as ipamorelin trigger it through a second receptor, the ghrelin receptor. The pairing hypothesis, amplify and trigger together, is why CJC-1295 and ipamorelin became the standard combination, and it is the format we supply as one combined pen. Sermorelin studies use the same logic when it is paired with GHRP-class compounds.
It is longer-acting rather than "stronger": single doses elevated GH and IGF-1 for days in human studies, against minutes of activity for sermorelin. Sustained exposure and pulse-preserving stimulation are different exposure profiles, not a simple potency ranking.
Yes. Sermorelin was marketed as Geref for growth-hormone deficiency before being discontinued. No GHRH analogue in this comparison holds a current marketing authorisation.
CJC-1295 combined with ipamorelin in one pre-loaded pen. Sermorelin is not in our range.
No. GHRH analogues and GH secretagogues are prohibited at all times under WADA.
This page is educational and intended for research and informational use only. It is not medical advice, a treatment recommendation, or dosing guidance, and it makes no promises about outcomes. Where a compound has held a marketing authorisation, approved medicines are supplied only through licensed pharmacies with a prescription. Body Pharm EU supplies research-grade materials for laboratory use, not approved medicines, and nothing here should be read as a substitute for advice from a qualified healthcare professional.
Both are GHRH analogues. The interesting difference is not potency. It is that one of them was once a licensed medicine with a real clinical record, and the other has never progressed past early-phase studies. That asymmetry is unusual in this catalogue and worth reading carefully.
Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab 2006;91(3):799–805. PMID 16352683; Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. JCEM 2006;91(12):4792–7. PMID 17018654
Nothing has compared the two directly. What follows is assembled from separate literatures, and the two literatures are not of the same type: one is clinical use history, the other early-phase pharmacology.
Sermorelin mirrors the natural hormone and clears within minutes. CJC-1295 with the DAC modification binds albumin and stretches exposure across days: Teichman et al. estimated a half-life of 5.8 to 8.1 days, with growth hormone elevated for six days or more and IGF-1 for nine to eleven after a single injection.
Sustained elevation and pulse-preserving stimulation are different exposure profiles, not a potency ranking. Whether either is preferable is a genuinely open question: the pulse is how growth-hormone physiology naturally operates, while sustained elevation produces larger cumulative IGF-1 exposure.
Search interest in “CJC-1295 DAC vs no DAC” exceeds interest in either compound alone, and the distinction is real. Without DAC, CJC-1295 is essentially modified GRF 1-29 and behaves as a brief pulse-preserving signal, much closer to sermorelin than to the multi-day profile above.
The two versions share a name and very little else in exposure terms. Any figure that does not specify which version it refers to is unusable, and this comparison changes shape depending on the answer.
Sermorelin was an approved medicine, marketed as Geref for growth-hormone deficiency, before being discontinued for commercial rather than safety reasons. Its human safety record therefore comes from real clinical use.
CJC-1295 never progressed past early-phase studies: two randomised, placebo-controlled trials of 28 and 49 days in healthy adults.
Neither holds a current marketing authorisation. Both are prohibited at all times under WADA.
That is the theoretical objection to a long-acting analogue, and Ionescu and Frohman addressed it directly in 2006, reporting that pulsatile secretion persists during continuous stimulation by CJC-1295. A real answer to a real objection, which is more than most claims in this category have.
CJC-1295 combined with ipamorelin in one pre-loaded pen; the background is at the CJC-1295 & Ipamorelin overview. Sermorelin is not in our range. The pairing logic is at CJC-1295 vs Ipamorelin and the class at growth hormone peptides.
We use cookies for analytics and marketing to improve your experience. You can accept or reject non-essential cookies. Privacy Policy